Skip to main content
. Author manuscript; available in PMC: 2019 Jan 22.
Published in final edited form as: Cancer Discov. 2018 Jan 4;8(3):288–303. doi: 10.1158/2159-8290.CD-16-1406

Figure 4.

Figure 4.

(A) Schema for prospective study of first-line abiraterone in mCRPC patients, with pre-treatment blood draw followed CTC assessments using digital CTCM Score and immunofluorescence cell imaging for CTC enumeration. (B) Graph of relationship between digital CTCM Score and CTC enumeration based on cell imaging at the pre-treatment time point. (C, D) Kaplan-Meier curves for overall survival (OS) and radiographic progression-free survival (R-PFS) by CTCM Score at the pretreatment time point. (E, F) Kaplan-Meier curves for overall survival (OS) by HOXB13 and AR-V7 CTC signal at the pretreatment time point. 5 patients had pre­treatment data available for HOXB13 but not for AR-V7. (G) Graph of relationship between HOXB13 and AR-V7 CTC signal (transcripts/mL blood) for CTC samples at the pre-treatment time point for patients for whom data was available for both HOXB13 and AR-V7. Red squares represent patients who died within 12 months of treatment initiation, and blue circles represent those who were alive.